- Home
- BAFN vs ANTX Comparison
BAFN vs ANTX Comparison
Compare BAFN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- ANTX
- Stock Information
- Founded
- BAFN 1999
- ANTX 2017
- Country
- BAFN United States
- ANTX United States
- Employees
- BAFN N/A
- ANTX N/A
- Industry
- BAFN Savings Institutions
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- ANTX Health Care
- Exchange
- BAFN Nasdaq
- ANTX Nasdaq
- Market Cap
- BAFN 40.6M
- ANTX 34.4M
- IPO Year
- BAFN N/A
- ANTX 2022
- Fundamental
- Price
- BAFN $8.34
- ANTX $1.21
- Analyst Decision
- BAFN
- ANTX Buy
- Analyst Count
- BAFN 0
- ANTX 2
- Target Price
- BAFN N/A
- ANTX $2.00
- AVG Volume (30 Days)
- BAFN 8.2K
- ANTX 95.1K
- Earning Date
- BAFN 10-30-2025
- ANTX 11-12-2025
- Dividend Yield
- BAFN 2.91%
- ANTX N/A
- EPS Growth
- BAFN N/A
- ANTX N/A
- EPS
- BAFN N/A
- ANTX N/A
- Revenue
- BAFN $58,931,000.00
- ANTX N/A
- Revenue This Year
- BAFN N/A
- ANTX N/A
- Revenue Next Year
- BAFN N/A
- ANTX N/A
- P/E Ratio
- BAFN N/A
- ANTX N/A
- Revenue Growth
- BAFN N/A
- ANTX N/A
- 52 Week Low
- BAFN $6.40
- ANTX $0.98
- 52 Week High
- BAFN $19.75
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- BAFN 35.33
- ANTX 47.90
- Support Level
- BAFN $8.05
- ANTX $1.13
- Resistance Level
- BAFN $8.65
- ANTX $1.26
- Average True Range (ATR)
- BAFN 0.32
- ANTX 0.07
- MACD
- BAFN -0.11
- ANTX -0.00
- Stochastic Oscillator
- BAFN 18.85
- ANTX 32.00
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.